600789
vs
S
Shanghai Composite
600789
Over the past 12 months, Shandong Lukang Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of -5% compared to the Shanghai Composite's +22% growth.
Stocks Performance
600789 vs Shanghai Composite
Performance Gap
600789 vs Shanghai Composite
Performance By Year
600789 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shandong Lukang Pharmaceutical Co Ltd
Glance View
In the bustling province of Shandong, a prominent player in the pharmaceutical industry, Shandong Lukang Pharmaceutical Co Ltd, traces its roots back to the mid-20th century, embodying the spirit of innovation in healthcare. This enterprise initially embarked on its journey as a penicillin producer, quickly adapting to the shifts in global healthcare demands by expanding its product line to include a broad spectrum of antibiotics, anti-infectives, and other essential medications. With its headquarters strategically located in Jining, Shandong Lukang leverages sophisticated technology and a rich legacy of expertise to manufacture products that cater to both domestic and international markets. The company's revenue streams are a testament to its diversified approach in the pharmaceutical sector. Primarily, Shandong Lukang excels in the research, development, production, and sale of pharmaceuticals, with antibiotics standing at its core. However, the company has adeptly diversified its operations by venturing into the production of veterinary drugs and biochemical products, creating a robust portfolio that ensures steady growth. By maintaining rigorous quality control and a commitment to innovation, it has positioned itself as a reliable supplier in both public and private healthcare sectors, underpinning its financial success through sustained partnerships and strategic market alliances. This solid foundation ensures that Shandong Lukang remains resilient amid the ever-evolving dynamics of the global pharmaceutical landscape.
